J. Steinbach

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Joachim P. Steinbach, J P Steinbach, J. Steinbach, Joachim P Steinbach, J Steinbach, Joachim Steinbach, J. P. Steinbach, Joachim Peter Steinbach, J.p. Steinbach, Joachim-peter Steinbach
Publication record
288 papers · 15,511 citations · H-index 59

PAPERS

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
20231 citationsauthor #12
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
202388 citationsauthor #34
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations
20235 citationsauthor #14
Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma
20231 citationsauthor #4
Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
20231 citationsauthor #20
Neurosurgical Interventions for Cerebral Metastases of Solid Tumors.
20233 citationsauthor #5
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma
20227 citationsauthor #9
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
202225 citationsauthor #6
The Acute Superficial Siderosis Syndrome — Clinical Entity, Imaging Findings, and Histopathology
20227 citationsauthor #3
NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL
20220 citationsauthor #9
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression
202217 citationsauthor #9
Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment
20220 citationsauthor #9
CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT
20220 citationsauthor #25
Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
202215 citationsauthor #12
Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management
20224 citationsauthor #5
AMP-kinase mediates adaptation of glioblastoma cells to conditions of the tumour microenvironment
20225 citationsauthor #12
DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis
202234 citationsauthor #21
Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
202211 citationsauthor #5
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
20225 citationsauthor #5
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
2022388 citationsauthor #4
Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis
202210 citationsauthor #21
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
202235 citationsauthor #17
Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience
202217 citationsauthor #31
Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression
202215 citationsauthor #11
Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
20222 citationsauthor #8
DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment
202226 citationsauthor #21
High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors
20229 citationsauthor #6
MR imaging profile and histopathological characteristics of tumour vasculature, cell density and proliferation rate define two distinct growth patterns of human brain metastases from lung cancer
20227 citationsauthor #5
BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA
20210 citationsauthor #5
BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS
20210 citationsauthor #9
Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial
202141 citationsauthor #12
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
20214 citationsauthor #9
Chemotherapy for adult patients with spinal cord gliomas.
20214 citationsauthor #11
OS06.2A Local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells
20211 citationsauthor #7
Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy
20213 citationsauthor #7
OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo
20214 citationsauthor #14
Correction: Serine-dependent redox homeostasis regulates glioblastoma cell survival
20211 citationsauthor #6
P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival
20210 citationsauthor #8
Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas
20213 citationsauthor #11
Single-shot bevacizumab for cerebral radiation injury
202114 citationsauthor #5
A Paravermal Trans-Cerebellar Approach to the Posterior Fossa Tumor Causes Hypertrophic Olivary Degeneration by Dentate Nucleus Injury
20218 citationsauthor #8
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
202153 citationsauthor #14
Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma
202111 citationsauthor #8
A vaccine targeting mutant IDH1 in newly diagnosed glioma
2021334 citationsauthor #24
OS05.9.A Short-term fasting in glioma patients - Analysis of diet diaries and metabolic parameters of the ERGO2 trial
20210 citationsauthor #12
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
202127 citationsauthor #4
Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide
202128 citationsauthor #7
Serine-dependent redox homeostasis regulates glioblastoma cell survival
202077 citationsauthor #6
ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma.
202077 citationsauthor #17
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial
202012 citationsauthor #4
Serine-dependent redox homeostasis regulates glioblastoma cell survival
20202 citationsauthor #6
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma
20208 citationsauthor #14
18F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience
202063 citationsauthor #8
Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer
20202 citationsauthor #9
AMPK activation protects astrocytes from hypoxia-induced cell death
202017 citationsauthor #13
Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition
202014 citationsauthor #5
Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial
202021 citationsauthor #11
P06.13 A novel local treatment approach? Targeted immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors through locally administered HER2-AAVs in combination with CAR-NK cells
20201 citationsauthor #6
Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
202011 citationsauthor #9
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma.
202055 citationsauthor #10
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
202048 citationsauthor #12
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.
202028 citationsauthor #20
Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death
202010 citationsauthor #15
Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab
20194 citationsauthor #6
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
201927 citationsauthor #10
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide
201921 citationsauthor #5
EGFR and mTOR as therapeutic targets in glioblastoma
20197 citationsauthor #3
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
201929 citationsauthor #4
Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients
201911 citationsauthor #3
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
201959 citationsauthor #7
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
201935 citationsauthor #10
OS6.5 ERGO2: A prospective randomized trial of a 9-day schedule of calorically restricted ketogenic diet and fasting or standard diet in addition to re-irradiation for malignant glioma
20191 citationsauthor #16
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.
20190 citationsauthor #10
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
2019181 citationsauthor #8
Loss of cell-matrix contact increases hypoxia-inducible factor-dependent transcriptional activity in glioma cells.
201913 citationsauthor #3
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
2019393 citationsauthor #4
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
201980 citationsauthor #6
Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas
2019138 citationsauthor #19
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
201926 citationsauthor #5
P12.04 Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity in vivo
20192 citationsauthor #7
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
20191 citationsauthor #6
Delay in diagnosing patients with right-sided glioblastoma induced by hemispheric-specific clinical presentation
201910 citationsauthor #4
OS2.2 Chemotherapy for spinal gliomas in adults
20190 citationsauthor #11
Delayed Occurrence of Hypertrophic Olivary Degeneration after Therapy of Posterior Fossa Tumors: A Single Institution Retrospective Analysis
20199 citationsauthor #6
INNV-22. TO TREAT OR NOT TO TREAT – TREATMENT OUTCOMES OF VERY ELDERLY GLIOBLASTOMA PATIENTS
20190 citationsauthor #6
P14.96 Gliomatosis cerebri imaging pattern: a treatment-independent marker for worse overall survival in WHO grade II and III gliomas
20190 citationsauthor #10
In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy
201918 citationsauthor #4
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL
20192 citationsauthor #4
P01.101 Treatment and survival of patients with lower grade glioma according to the 2007 and the 2016 WHO classification: A retrospective analysis of 423 patients.
20180 citationsauthor #7
OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network
20180 citationsauthor #15
Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation
201821 citationsauthor #7
Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma
201811 citationsauthor #9
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial
201812 citationsauthor #6
Fitting algorithms and baseline correction influence the results of non‐invasive in vivo quantitation of 2‐hydroxyglutarate with 1H‐MRS
201818 citationsauthor #6
P04.47 Nrf2 mediates hypoxic tolerance in human glioblastoma cells
20180 citationsauthor #6
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival
201828 citationsauthor #12
Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
201813 citationsauthor #6
Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network
201828 citationsauthor #7
CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival
201828 citationsauthor #11
Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells
201828 citationsauthor #10

TIMELINE

1994 3 citations

1995 384 citations

1996 17 citations

1997 533 citations

1998 489 citations

1999 20 citations

2001 23 citations

2002 333 citations

2003 116 citations

2004 418 citations

2005 202 citations

2006 242 citations

2007 1,428 citations

2008 48 citations

2009 904 citations

2010 767 citations

2011 489 citations

2012 1,303 citations

2013 465 citations

2014 1,528 citations

2015 869 citations

2016 1,423 citations

2017 343 citations

2018 365 citations

2019 1,067 citations

2020 446 citations

2021 536 citations

2022 639 citations

2023 99 citations

J. Steinbach

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT